Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with<i>Mycobacterium tuberculosis</i>and Boosts Prior Bacillus Calmette-Guérin Immunity

Dietrich, Jes; Andersen, Claire Swetman; Rappuoli, Rino; Doherty, T. Mark; Jensen, Charlotte; Andersen, Peter

doi:10.4049/jimmunol.177.9.6353

Cited by 166 publications

(104 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, purified Mycobacterium tuberculosis fusion Ag85B-early secreted antigenic target 6 kDa (Ag85B-ESAT6) has been shown to induce potent Ag-specific immune responses when coadministered i.n. with an LT-based adjuvant generating significant immune responses and protection after M. tuberculosis challenge (9,10).…”

mentioning

confidence: 99%

NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant

Hall

Clare

Dougan

2010

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant

Hall

Clare

Dougan

2010

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Increasing evidence has indicated the effectiveness of vaccination at the mucosal site compared with vaccination via other routes for inducing protection from mucosal infectious diseases (15,55). Numerous studies have verified that mucosal immunity may provide unique advantages for protection against Mtb infection (34,(56)(57)(58). Therefore, any vaccines or vaccination strategies that are able to elicit the mucosal immune response may enhance the efficacy of protection against Mtb infection.…”

Section: Discussionmentioning

confidence: 99%

“…Loss of RD1 was hypothesized to be the contributing factor for the attenuation of BCG (27,28); therefore, RD1-encoded CFP10 and ESAT6 have often been selected as potential antigen candidates in the development of novel anti-TB vaccines (19,(29)(30)(31)(32). In addition to CFP10 and ESAT6, Ag85A and Ag85B have also been widely employed in anti-TB vaccine development (32)(33)(34)(35)(36).…”

Section: Introductionmentioning

confidence: 99%

Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice

Deng

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Tuberculosis (TB) remains to be a prevalent health issue worldwide. At present, Mycobacterium bovis Bacillus Calmette Guerin (BCG) is the singular anti-TB vaccine available for the prevention of disease in humans; however, this vaccine only provides limited protection against Mycobacterium tuberculosis (Mtb) infection. Therefore, the development of alternative vaccines and strategies for increasing the efficacy of vaccination against TB are urgently required. The present study aimed to evaluate the ability of a recombinant adenoviral vector (Ad5-CEAB) co-expressing 10-kDa culture filtrate protein, 6-kDa early-secreted antigenic target, antigen 85 (Ag85) A and Ag85B of Mtb to boost immune responses following primary vaccination with BCG in mice. The mice were first subcutaneously primed with BCG and boosted with two doses of Ad5-CEAB via an intranasal route. The immunological effects of Ad5-CEAB boosted mice primed with BCG were then evaluated using a series of immunological indexes. The results demonstrated that the prime-boost strategy induced a potent antigen-specific immune response, which was primarily characterized by an enhanced T cell response and increased production of cytokines, including interferon-γ, tumor necrosis factor-α and interleukin-2, in mice. In addition, this vaccination strategy was demonstrated to have an elevated humoral response with increased concentrations of antigen-specific bronchoalveolar lavage secretory immunoglobulin (Ig)A and serum IgG in mice compared with those primed with BCG alone. These data suggested that the regimen of subcutaneous BCG prime and mucosal Ad5-CEAB boost was a novel strategy for inducing a broad range of antigen-specific immune responses to Mtb antigens in vivo, which may provide a promising strategy for further development of adenoviral-based vaccine against Mtb infection. IntroductionTuberculosis (TB) is one of the most prevalent infectious diseases worldwide, accounting for ~1.4 million mortalities and 8.7 million novel cases annually, which occurs as a results of Mycobacterium tuberculosis (Mtb) infection (1). Due to Mtb reactivation at a latent state in immunocompromised individuals, slow progress in dealing with drug-resistant Mtb infection and the co-infection of Mtb with human immunodeficiency virus, the global burden of TB remains high, particularly in developing countries (2,3).Effective vaccines are of key importance in ending the global TB epidemic (1). However, a consistently effective vaccine is not currently available. The only available TB vaccine, attenuated Mycobacterium bovis Bacillus Calmette Guerin (BCG) has made a marked contribution to Mtb infection control, especially in juvenile population and newborns (4). However, BCG does not provide effective protection for all age groups, particularly in adults; its protective efficacy is highly varied from different trials, with certain studies observing negative effects associated with BCG revaccination (0-80%) (5,6). Therefore, the development of more effective vaccines or feasible...

show abstract

“…For example one called hybrid-1 contains antigens 85B and ESAT-6 (Dietrich J et al 2006). Few innovations have gone into post exposure vaccines.…”

Section: Tb Vaccinesmentioning

confidence: 99%

Advances in the Diagnosis, Treatment and Control of HIV Associated Tuberculosis

Kirenga¹,

Chanda²,

Muwonge³

et al. 2012

African Journal of Infectious Diseases

View full text Add to dashboard Cite

SummaryThere has been an increase in the number of published tuberculosis/HIV (TB/HIV) research findings in recent times. The potential impact of these findings on routine care has informed this review which aims at discussing current concepts and practices underpinning TB/HIV care and control. Any HIV infected person with a cough of any duration is currently considered a TB suspect. Preliminary results also show that the diagnostic yield of same day sputum samples (front loading) is comparable to two-day samples. Laboratory diagnosis is shifting from Ziehl-Neelsen (ZN) smear microscopy and solid culture to fluorescent microscopy, molecular tests and liquid culture. Concomitant TB/HIV therapy improves survival and WHO has recommended ART for all TB/HIV patients. Unless CD4 cell counts are less than 50 cells/µl, ART can be deferred until end of intensive phase. Evidence of survival benefit at high CD4 cell counts is still lacking. New TB drugs and treatment shortening studies are underway but so far no new TB drugs has been added to the current arsenal and treatment duration still remains six months or more. WHO has recommended the 3Is (intensified TB case finding, isoniazid prophylaxis and infection control) for TB/HIV control in addition to effective therapy, Antiretroviral therapy and TB vaccines. There has been immense progress in TB/HIV research, however optimal management of HIV-Infected TB patients, will require further research and appropriate translation of emerging evidence to policy and practice. IntroductionThe burden of tuberculosis (TB) among human immunodeficiency virus (HIV) infected persons continues to represent a major public health problem. Of the 9.4 million new TB cases reported in 2009, 1.1 million were HIV infected of which 380, 000 died (WHO Global Tuberculosis control report, 2010). Antiretroviral therapy (ART) reduces person and population risk of TB by 90% and 60% respectively (Lawn S et al., 2005, Badri et al., 2002. Unfortunately only 37% of TB/HIV patients who qualified to receive ART were initiated on ART in 2009 (WHO Global Tuberculosis control report, 2010). There has been an increase in basic, clinical and public health TB/HIV research, shedding new light on diagnosis, treatment and control of TB/HIV; hence those involved in the field of TB/HIV need to constantly update their knowledge in this field. The purpose of this review is to describe, discuss and summarize current concepts and practices in the diagnosis, treatment and control of HIV associated tuberculosis. Diagnosis of HIV associated tuberculosisTB symptoms: One of the major advances in the clinical diagnosis of TB/HIV has been the demonstration in number of studies that TB/HIV patients with cough should be tested for TB irrespective of the duration of the cough (Kevin et al., 2010), Ngadaya et al., 2009). In a study that evaluated the performance of different combination of TB symptoms, it was found that the best symptom combination included two predictors; fever of any duration in the previous 4 weeks plus cough of a...

show abstract

Mucosal Administration of Ag85B-ESAT-6 Protects against Infection withMycobacterium tuberculosisand Boosts Prior Bacillus Calmette-Guérin Immunity

Cited by 166 publications

References 31 publications

NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant

NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant

Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice

Advances in the Diagnosis, Treatment and Control of HIV Associated Tuberculosis

Contact Info

Product

Resources

About